RBC Capital analyst Gregory Renza raised the firm’s price target on Fusion Pharmaceuticals to $16 from $12 and keeps an Outperform rating on the shares. FPI-2265 stands as the company’s most clinically advanced asset in development for metastatic castration-resistant prostate cancer, with a Phase 2 update coming in April, the analyst tells investors in a research note. The firm maintains its positive stance on risk-reward for the stock, adding that the upcoming disclosure has been largely de-risked by prior IST studies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on FUSN:
- Fusion licensing agreement ‘hugely positive,’ says B. Riley
- Fusion Pharmaceuticals Expands Cancer Treatment Rights and Settles Review
- Fusion Pharmaceuticals enters license agreement with Heidelberg Univ., Euratom
- Leerink MedaCorp specialist holds an analyst/industry conference call
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call